3 articles
Retatrutide explained in depth: how GLP-1, GIP, and glucagon receptor agonism work together, what the phase 2 and phase 3 trial data actually shows, who is a clinical candidate, and what monitoring is required.
The TRIUMPH 4 phase 3 trial data on retatrutide is remarkable. But the side effects most sources skip (26% lean muscle loss, dopamine suppression and dosing traps) are the reason physician supervision matters. This is what the studies actually show.
Retatrutide in Thailand: what the triple-agonist (GLP-1/GIP/glucagon) is, what the trial data shows, how it compares to semaglutide and tirzepatide, its availability and legal status, side effects to monitor, and why doctor-supervised, clinical-grade use matters.